[{"id":"9de9a1df-22ec-481b-a91e-eefe5c853bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02791334","created_at":"2021-01-18T13:42:09.109Z","updated_at":"2024-07-02T16:34:59.807Z","phase":"Phase 1","brief_title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT02791334","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/29/2016","start_date":" 06/29/2016","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-31"},{"id":"cb99bd61-d78f-4c46-9fbc-8d8d9c4ae1be","acronym":"","url":"https://clinicaltrials.gov/study/NCT02745769","created_at":"2021-01-18T13:27:10.116Z","updated_at":"2024-07-02T16:37:02.234Z","phase":"Phase 1a/1b","brief_title":"A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents","source_id_and_acronym":"NCT02745769","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR • CTLA4","pipe":" | ","alterations":" RAS wild-type","tags":["EGFR • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/21/2016","start_date":" 10/21/2016","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 01/22/2019","study_completion_date":" 01/22/2019","last_update_posted":"2019-03-05"},{"id":"7bcb3819-21cf-473f-a1af-86077a19288b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01285037","created_at":"2021-01-18T05:12:51.722Z","updated_at":"2024-07-02T16:37:13.792Z","phase":"Phase 1","brief_title":"A Study of LY2801653 in Advanced Cancer","source_id_and_acronym":"NCT01285037","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • gemcitabine • Cyramza (ramucirumab) • merestinib (LY2801653)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 09/09/2009","start_date":" 09/09/2009","primary_txt":" Primary completion: 07/21/2017","primary_completion_date":" 07/21/2017","study_txt":" Completion: 09/11/2017","study_completion_date":" 09/11/2017","last_update_posted":"2018-02-20"}]